Siponimod modulates the reaction of microglial cells to pro-inflammatory stimulation

Siponimod (Mayzent®), a sphingosine 1-phosphate receptor (S1PR) modulator which prevents lymphocyte egress from lymphoid tissues, is approved for the treatment of relapsing-remitting- and active secondary progressive multiple sclerosis. It can cross the blood-brain-barrier (BBB) and selectively binds to S1PR1 and S1PR5 expressed by several cell populations of the central nervous system (CNS) including microglia. To investigate wether Siponimod modulates the genetic signature of inflammed microglia, we performed a transcriptome analyses of primary rat microglial cells stimulated with LPS and With or Without Siponimod.